Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer

被引:18
作者
Le, T
Faught, W
Hopkins, L
Fung, MFK
机构
[1] Univ Ottawa, Div Gynecol Oncol, Dept Obstet & Gynecol, Ottawa, ON, Canada
[2] Univ Alberta, Dept Obstet & Gynecol, Div Gynecol Oncol, Edmonton, AB, Canada
关键词
interval debulking; neoadjuvant chemotherapy; ovarian cancer;
D O I
10.1111/j.1525-1438.2005.00134.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this article was to review the experience with neoadjuvant chemotherapy and interval surgical debulking in patients with metastatic epithelial ovarian cancer. A retrospective chart review was carried out to identify patients treated with neoadjuvant platinum/Taxol chemotherapy and interval debulking. Cox regression modeling was used to identify significant predictors of progression-free interval. The Kaplan-Meier method was used to estimate the survival statistic for the study group. Sixty-one patients were identified after being treated with neoadjuvant chemotherapy and interval debulking surgeries. All surgeries were performed after three cycles of platinum/Taxol combination chemotherapy. Eighty percent of patients had a residual disease status of 2 cm or less after surgery. Suboptimal debulking was statistically associated with tumor involvement of the upper abdominal organs (P < 0.001) and nonnormalization of CA125 before surgery (P = 0.03). The perioperative complication rate was 7%. At a mean follow-up time of 19 months, 77% of patients were still alive. Cox regression modeling identified the microscopic tumor residual status as the only significant predictor of progression-free interval. The estimated median survival for the group was 41.70 months (95% confidence interval = 13.84-69.56 months). Neoadjuvant chemotherapy with interval debulking surgery appeared to be safe and feasible in patients with metastatic epithelial ovarian carcinoma.
引用
收藏
页码:770 / 775
页数:6
相关论文
共 18 条
[1]  
Allen D. G., 1995, European Journal of Gynaecological Oncology, V16, P349
[2]   Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study [J].
Chan, YM ;
Ng, TY ;
Ngan, HYS ;
Wong, LC .
GYNECOLOGIC ONCOLOGY, 2003, 88 (01) :9-16
[3]   Critique of surgical cytoreduction in advanced ovarian cancer [J].
Covens, AL .
GYNECOLOGIC ONCOLOGY, 2000, 78 (03) :269-274
[4]   THE INFLUENCE OF CYTOREDUCTIVE SURGERY ON RECURRENCE-FREE INTERVAL AND SURVIVAL IN SMALL-VOLUME STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
HOSKINS, WJ ;
BUNDY, BN ;
THIGPEN, JT ;
OMURA, GA .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :159-166
[5]   SURGICAL STAGING AND CYTOREDUCTIVE SURGERY OF EPITHELIAL OVARIAN-CANCER [J].
HOSKINS, WJ .
CANCER, 1993, 71 (04) :1534-1540
[6]  
Kayikçioglu F, 2001, INT J GYNECOL CANCER, V11, P466
[7]  
LAWTON FG, 1989, OBSTET GYNECOL, V73, P61
[8]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[9]   Results of interval debulking surgery in advanced stage ovarian cancer:: an exposed-non-exposed study [J].
Morice, P ;
Brehier-Ollive, D ;
Rey, A ;
Atallah, D ;
Lhommé, C ;
Pautier, P ;
Pomel, C ;
Camatte, S .
ANNALS OF ONCOLOGY, 2003, 14 (01) :74-77
[10]   LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR-ANALYSIS IN ADVANCED OVARIAN-CARCINOMA - THE GYNECOLOGIC-ONCOLOGY-GROUP EXPERIENCE [J].
OMURA, GA ;
BRADY, MF ;
HOMESLEY, HD ;
YORDAN, E ;
MAJOR, FJ ;
BUCHSBAUM, HJ ;
PARK, RC .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1138-1150